Screener
Krystal Biotech, Inc. KRYS Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 7:06 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001711279-26-000043
| (in thousands, except par value) | March 31,2026 | December 31,2025 |
|---|---|---|
| Total current liabilities | 107,802 | 102,942 |
| Lease liability | 7,312 | 7,568 |
| Other long-term liabilities | 5,124 | 3,724 |
| Total liabilities | 120,238 | 114,234 |
| Commitments and contingencies (see note 7) | ||
| Stockholders’ equity | ||
| Common stock; $0.00001 par value; 80,000 shares authorized as of March 31, 2026 and December 31, 2025; 29,437 and 29,192 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively. | — | — |
| Additional paid-in capital | 1,198,257 | 1,194,261 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Krystal Biotech, Inc.'s total liabilities?
- Krystal Biotech, Inc. (KRYS) reported total liabilities of $120.24M in Q1 2026.
- How has Krystal Biotech, Inc.'s total liabilities changed year-over-year?
- Krystal Biotech, Inc.'s total liabilities increased by 34.0% year-over-year, from $89.74M to $120.24M.
- What is the long-term trend for Krystal Biotech, Inc.'s total liabilities?
- Over 5 years (2020 to 2025), Krystal Biotech, Inc.'s total liabilities has grown at a 43.5% compound annual growth rate (CAGR), from $18.76M to $114.23M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Krystal Biotech, Inc.'s total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude